GlassScriptPhysician profile
Richard Christoper Kirkpatrick
NPI 1821074980
$5,186.32
in general payments reported to CMS, 2019-2025
33 companies · $676 in 2025
The $676 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $437 · 2021: $616 · 2022: $679 · 2023: $891 · 2024: $1,150 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $593.78 | 2019-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $592.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $397.07 | 2022-2025 | Sotyktu, Opdivo |
| Sun Pharmaceutical Industries INC. | $328.21 | 2019-2025 | Odomzo, Blu-U |
| Leo Pharma INC. | $300.19 | 2019-2024 | Adbry |
| Janssen Biotech, INC. | $213.27 | 2021-2024 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $204.99 | 2019-2025 | |
| Pfizer INC. | $202.65 | 2019-2025 | |
| Genentech USA, INC. | $171.96 | 2019-2020 | |
| Dermavant Sciences, INC. | $132.57 | 2023-2024 | Vtama |
| Lilly USA, LLC | $128.72 | 2021-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $113.95 | 2019-2024 | |
| Almirall LLC | $99.09 | 2019-2025 | Klisyri |
| Incyte Corporation | $87.70 | 2022-2025 | Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $75.33 | 2023-2024 | Bimzelx |
| Amgen INC. | $68.89 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.00 | 2019 | |
| Strata Skin Sciences, INC. | $59.30 | 2019-2023 | Xtrac |
| Celgene Corporation | $42.48 | 2019-2024 | Sotyktu |
| Sebela Pharmaceuticals INC. | $36.39 | 2020 | |
| Dusa Pharmaceuticals, INC. | $34.80 | 2019 | |
| Biofrontera INC. | $34.39 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $32.69 | 2020 | |
| Verrica Pharmaceuticals INC. | $29.82 | 2024 | Ycanth |
| Organon LLC | $28.65 | 2025 | Vtama |
| Dermira, INC. | $27.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.03 | 2025 | Spevigo |
| Botanix Sb INC | $16.67 | 2025 | Sofdra |
| Esperion Therapeutics, INC. | $15.95 | 2024 | Nexletol |
| Promius Pharma LLC | $15.70 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.32 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.